Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
SPRO Transcript
Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript
Neutral8-12
Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript
Unknown3-27
The earnings call highlights significant financial risks with an 80% revenue decline and increased R&D expenses, leading to a substantial net loss. Clinical trial failures and regulatory uncertainties amplify the negative outlook. The Q&A reveals management's evasiveness on trial specifics, further eroding confidence. Lack of shareholder return initiatives and competitive market pressures exacerbate concerns. Without positive catalysts or strategic plans, the stock is likely to experience a strong negative reaction.
Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript
Unknown3-27
The earnings call reveals significant financial challenges, with a drastic revenue decline and increased losses. The clinical trial for SPR720 failed to meet its primary endpoint, posing risks. The lack of a shareholder return plan and increased R&D expenses further dampen sentiment. The Q&A section highlights management's uncertainty and lack of clear guidance, exacerbating concerns. Overall, the combination of financial struggles, clinical setbacks, and unclear strategic direction suggests a strong negative sentiment, likely leading to a significant stock price decline.
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
Neutral8-9
SPRO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
